EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

CML in the very elderly: the impact of comorbidities and TKI selection in a real-life multicenter study

Alon Rozental, Erez Halperin, Chiya Leibovitch, Meirav Barzili, Maya Koren- Michowitz, Adrian Duek, Uri Rozovski, Martine Extermann, Pia Raanani, Adi Shacham-Abulafia

Annals of Hematology · 2024

DOI: 10.1007/s00277-024-05828-3 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Annals of Hematology, 2024. Verfasst von Alon Rozental und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Beilinson Campus, Petah-Tikva, Israel. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Comorbidity. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tel Aviv University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tyrosine kinase inhibitors (TKIs) have greatly improved chronic myeloid leukemia (CML) treatments, with survival rates close to the general population. Yet, for the very elderly, robust data remains limited. This study focused on assessing comorbidities, treatment approaches, responses, and survival for elderly CML patients. Our study was conducted on 123 elderly (≥ 75 years) CML patients across four centers in Israel and Moffitt Cancer Center, USA. The median age at diagnosis was 79.1 years, with 44.7% being octogenarians. Comorbidities were very common; cardiovascular risk factors (60%), cardiovascular diseases (42%), with a median age-adjusted Charlson Comorbidity Index (aaCCI) of 5. Imatinib was the leading first-line therapy (69%), while the use of second-generation TKIs increased post-2010. Most patients achieved a major molecular response (MMR, 66.7%), and half achieved a deep molecular response (DMR, 50.4%). Over half (52.8%) of patients moved to second-line, and nearly a quarter (23.5%) to third-line treatments, primarily due to intolerance. Overall survival (OS) was notably longer in patients with an aaCCI score below 5, and in patients who attained DMR. Contrary to expectations, the Israeli cohort showed a shorter actual life expectancy than projected, suggesting a larger impact of CML on elderly survival. In summary, imatinib remains the main initial treatment, but second-generation TKIs are on the rise among elderly CML patients. Outcomes in elderly CML patients depend on comorbidities, TKI type, response, and age, underscoring the need for personalized therapy and additional research on TKI effectiveness and safety.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Kinase InhibitorsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveComorbidityHumansAgedMaleAged, 80 and overFemaleIsraelImatinib MesylateSurvival RateRetrospective StudiesTreatment Outcome

Stichwörter der Autor:innen

Chronic myeloid leukemiaComorbidityDrug toxicityGeriatric oncologySurvival analysisTreatment outcomeTyrosine kinase inhibitors

Substanzen

Protein Kinase InhibitorsImatinib Mesylate

Autor:innen und Institutionen

  • Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Beilinson Campus, Petah-Tikva, Israel.
  • Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
  • Senior Adult Oncology Program, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
  • Internal Medicine B, Ashdod Hospital, Samson Assuta, Ashdod, Israel.
  • Hematology and Hemato-Oncology Division, Tel Aviv Medical Center, Tel Aviv, Israel.
  • Shamir Medical Center, Department of Hematology, Zerifin, Israel.

Förderung

  • Tel Aviv University

Zitieren

APA

Rozental, A., Halperin, E., Leibovitch, C., Barzili, M., Michowitz, M. K., Duek, A., Rozovski, U., Extermann, M., Raanani, P., & Shacham-Abulafia, A. (2024). CML in the very elderly: the impact of comorbidities and TKI selection in a real-life multicenter study. Annals of Hematology. https://doi.org/10.1007/s00277-024-05828-3

Vancouver

Rozental A, Halperin E, Leibovitch C, Barzili M, Michowitz MK, Duek A, et al. CML in the very elderly: the impact of comorbidities and TKI selection in a real-life multicenter study. Annals of Hematology. 2024. doi:10.1007/s00277-024-05828-3

BibTeX
@article{Rozental2024,
  author = {Rozental, Alon and Halperin, Erez and Leibovitch, Chiya and Barzili, Meirav and Michowitz, Maya Koren- and Duek, Adrian and Rozovski, Uri and Extermann, Martine and Raanani, Pia and Shacham-Abulafia, Adi},
  title = {CML in the very elderly: the impact of comorbidities and TKI selection in a real-life multicenter study},
  journal = {Annals of Hematology},
  year = {2024},
  doi = {10.1007/s00277-024-05828-3}
}
Kostenlos starten →